Genomic Origin and EGFR-TKI Treatments of Pulmonary Adenosquamous Carcinoma

G. Lin,C. Li,P.S. Li, W.Z. Fang, H.P. Xu,Y.H. Gong,Z.F. Zhu,Y. Hu,W.H. Liang,Q. Chu,W.Z. Zhong, L. Wu, H.J. Wang,Z.J. Wang,Z.M. Li,J. Lin,Y.F. Guan,X.F. Xia,X. Yi, Q. Miao,B. Wu,K. Jiang,X.B. Zheng,W.F. Zhu,X.L. Zheng,P.S. Huang, W.J. Xiao,D. Hu, L.F. Zhang, X.R. Fan,Tony S.K. Mok,C. Huang

Annals of Oncology（2020）

引用 35|浏览153

暂无评分

摘要

•The adenocarcinoma component and squamous cell carcinoma component of adenosquamous carcinoma share a common clonal origin.•High incidence of trunk EGFR and TP53 mutation were noted in adenosqumous cell carcinoma, while the overall genomic profile of adenosqumous cell carcinoma is more similar to adenocarcinoma than squmous cell carcinoma.•EGFR-TKIs should be the standard first-line therapy for advanced stage adenosquamous carcinoma with EGFR mutation.

查看译文

关键词

adenosquamous carcinoma,clonal origin,EGFR,EGFR-TKI,genomic profile

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要